Diadexus, Inc. is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of their patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: OTCMKTS:DDXS
- CUSIP: N/A
- Web: www.diadexus.com/
- 50 Day Moving Avg: $1.11
- 200 Day Moving Avg: $1.54
- 52 Week Range: $0.01 - $5.40
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.01
- P/E Growth: 0.00
- Net Margins: -47.79%
- Return on Assets: -58.13%
- Average Volume: 24,020 shs.
Frequently Asked Questions for diaDexus (OTCMKTS:DDXS)
What is diaDexus' stock symbol?
diaDexus trades on the OTCMKTS under the ticker symbol "DDXS."
How were diaDexus' earnings last quarter?
diaDexus, Inc. (OTCMKTS:DDXS) posted its quarterly earnings results on Monday, October, 26th. The company reported ($0.34) EPS for the quarter, topping the Zacks' consensus estimate of ($0.69) by $0.35. View diaDexus' Earnings History.
Who are some of diaDexus' key competitors?
Some companies that are related to diaDexus include Banco Popolare (BPSAY), DAILY MAIL&GEN TST SPON (DMTGY), African Barrick Gold Ltd (ABGLY), Solvay S.A. (SVYZY), Tencent Holding (TCEHY), Nestle SA (NSRGY), Cable & Wireless Communications Plc (CWIXF), L'Oreal SA (LRLCY), Naspers (NPSNY), Allianz SE (AZSEY), Softbank Corp. (SFTBY), BASF SE (BASFY), Volkswagen AG (VLKAY), Reckitt Benckiser Group PLC (RBGLY), Australia & New Zealand Banking Group (ANZBY), National Australia Bank (NABZY), Heineken NV (HEINY) and Glencore International PLC, St. Helier (GLCNF).
Who are diaDexus' key executives?
diaDexus' management team includes the folowing people:
- Lori F. Rafield Ph.D., Chairman of the Board, Chief Executive Officer
- Leone D. Patterson, Chief Financial Officer
- Emi Zychlinsky Ph.D., Executive Vice President, Chief Technology Officer
- Christopher P. Lowe, Chief Accounting Officer
- Jonathan Ruais, Vice President of Marketing
- Kenneth C. Fang M.D., Chief Medical Officer
- R. Michael Richey, Chief Business Officer
- James R. Sulat, Director
- John T. Curnutte M.D. Ph.D., Independent Director
- Karen Drexler, Independent Director
How do I buy diaDexus stock?
Shares of diaDexus can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is diaDexus' stock price today?
MarketBeat Community Rating for diaDexus (OTCMKTS DDXS)MarketBeat's community ratings are surveys of what our community members think about diaDexus and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of diaDexus stock can currently be purchased for approximately $0.01.
Consensus Ratings for diaDexus (OTCMKTS:DDXS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for diaDexus (OTCMKTS:DDXS)
(Data available from 7/24/2015 forward)
|8/14/2015||Feltl & Co.||Downgrade||Buy -> Hold|
Earnings History for diaDexus (OTCMKTS:DDXS)Earnings History by Quarter for diaDexus (OTCMKTS DDXS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for diaDexus (OTCMKTS:DDXS)
Current Year EPS Consensus Estimate: $-1.50 EPS
Next Year EPS Consensus Estimate: $-1.50 EPS
Dividend History for diaDexus (OTCMKTS:DDXS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for diaDexus (OTCMKTS:DDXS)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for diaDexus (OTCMKTS:DDXS)
Latest Headlines for diaDexus (OTCMKTS:DDXS)
diaDexus (DDXS) Chart for Monday, July, 24, 2017